A recent European Urology Oncology study assessed the mortality risks, based on the Gleason score and clinical parameters, in patients with prostate cancer.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and meaningful survival in cisplatin-ineligible patients with locally advanced or metastatic